Literature DB >> 18727644

Differential effects of corticosteroids on the expression of cyclooxygenase-2, tumour necrosis factor-alpha and matrix metalloproteinase-9 in an animal model of migraine.

G-M Kim1, K-S Jin, C-S Chung.   

Abstract

Nitric oxide (NO) directly activates trigeminal afferents innervating the dura mater and up-regulates inflammatory mediators. We evaluated NO-mediated up-regulation of cyclooxygenase-2 (COX-2), tumour necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-9 (MMP-9), and the effect of glucocorticoid administration in an experimental animal model of migraine. COX-2 and TNF-alpha expression and MMP-9 activity were increased after continuous intravenous infusion of glyceryl trinitrate (GTN), a NO donor. Immunofluorescence staining demonstrated strong expression of these inflammatory mediators in the meningeal blood vessels. Methylprednisolone (MP) down-regulated MMP-9, which was reversed by RU486, a glucocorticoid receptor antagonist. COX-2 and TNF-alpha expression was not affected by MP or RU486 administration. These results suggest proinflammatory mediators are involved in the NO-mediated cascade of migraine pathogenesis. Further understanding of the activation of these inflammatory mediators at the transcriptional level may have therapeutic implications for future migraine treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18727644     DOI: 10.1111/j.1468-2982.2008.01667.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  9 in total

1.  Tetrandrine Alleviates Nociception in a Rat Model of Migraine via Suppressing S100B and p-ERK Activation in Satellite Glial Cells of the Trigeminal Ganglia.

Authors:  Guangcheng Qin; Bei Gui; Jingmei Xie; Lixue Chen; Lianlian Chen; Zhiwei Cui; Jiying Zhou; Ge Tan
Journal:  J Mol Neurosci       Date:  2017-11-16       Impact factor: 3.444

Review 2.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

3.  Nitroglycerin alters matrix remodeling proteins in THP-1 human macrophages and plasma metalloproteinase activity in rats.

Authors:  Anu Shilpa Krishnatry; Sun Mi Fung; Daniel A Brazeau; David Soda; Ho-Leung Fung
Journal:  Nitric Oxide       Date:  2010-12-13       Impact factor: 4.427

4.  Broad regulation of matrix and adhesion molecules in THP-1 human macrophages by nitroglycerin.

Authors:  Anu Shilpa Krishnatry; Daniel A Brazeau; Ho-Leung Fung
Journal:  Nitric Oxide       Date:  2009-10-15       Impact factor: 4.427

5.  The effects of vasoactive intestinal peptide on dura mater nitric oxide levels and vessel-contraction responses in sympathectomized rats.

Authors:  Fatma Tore; Orhan Tansel Korkmaz; Dilek Dogrukol-Ak; Nese Tunçel
Journal:  J Mol Neurosci       Date:  2009-11-20       Impact factor: 3.444

6.  Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats.

Authors:  Nagla Ahmed El-Nabarawy; Mahmoud Hassan Teaima; Doaa Ahmed Helal
Journal:  Drug Des Devel Ther       Date:  2019-11-21       Impact factor: 4.162

7.  Role of phosphorylated extracellular signal-regulated kinase, calcitonin gene-related peptide and cyclooxygenase-2 in experimental rat models of migraine.

Authors:  Xiaomeng Dong; Yaozhi Hu; Long Jing; Jinbo Chen
Journal:  Mol Med Rep       Date:  2015-04-15       Impact factor: 2.952

8.  Expression of artemin and GFRα3 in an animal model of migraine: possible role in the pathogenesis of this disorder.

Authors:  Hai-Qiong Shang; Yan Wang; Yan-Yan Mao; Li-Gang Kong; Gao-Ying Sun; Lei Xu; Dao-Gong Zhang; Yue-Chen Han; Jian-Feng Li; Hai-Bo Wang; Zhao-Min Fan
Journal:  J Headache Pain       Date:  2016-09-06       Impact factor: 7.277

9.  Plasma Levels of Cyclooxygenase-2 (COX-2) and Visfatin During Different Stages and Different Subtypes of Migraine Headaches.

Authors:  Chao Li; Qiushi Zhu; Qiu He; Junwei Wang; Fengzhi Wang; Hemin Zhang
Journal:  Med Sci Monit       Date:  2017-01-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.